Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRobert Berger, MD
Clinical InstructorAbout
Research
Publications
2024
Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids
Bar-Hai N, Ben-Yishay R, Arbili-Yarhi S, Herman N, Avidan-Noy V, Menes T, Mansour A, Awwad F, Balint-Lahat N, Goldinger G, Hout-Siloni G, Adileh M, Berger R, Ishay-Ronen D. Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids. Frontiers In Oncology 2024, 14: 1470379. PMID: 39469640, PMCID: PMC11513879, DOI: 10.3389/fonc.2024.1470379.Peer-Reviewed Original ResearchClass Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, Aharon S, Kosenko A, Zundelevich A, Berger R, Ishay-Ronen D. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells 2024, 13: 1506. PMID: 39273076, PMCID: PMC11394433, DOI: 10.3390/cells13171506.Peer-Reviewed Original ResearchA Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression
Majumder P, Grisanzio C, O'Connell F, Barry M, Brito J, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek W, Wang S, Ellwood-Yen K, Wu H, Sawyers C, Signoretti S, Hahn W, Loda M, Sellers W. A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer Cell 2024, 42: 1126. PMID: 38866454, DOI: 10.1016/j.ccell.2024.05.008.Commentaries, Editorials and Letters
2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis E, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal Of Clinical Oncology 2019, 38: 395-405. PMID: 31774688, PMCID: PMC7186583, DOI: 10.1200/jco.19.01638.Peer-Reviewed Original Research
2017
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
Golan T, Milella M, Ackerstein A, Berger R. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). Journal Of Experimental & Clinical Cancer Research 2017, 36: 192. PMID: 29282151, PMCID: PMC5745625, DOI: 10.1186/s13046-017-0668-0.Peer-Reviewed Original Research